drugset / Trial / NCT00813618
Study of MEDI 507 in the Treatment of Pediatric Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
Timeline
- Start
- 1999-09
- Primary completion
- 2004-06
- Completion
- 2004-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | 0.012 mg/kg | Intravenous |
| Subject | Siplizumab | Monoclonal antibody | 0.04 mg/kg | Intravenous |
| Subject | Siplizumab | Monoclonal antibody | 0.12 mg/kg | Intravenous |